CA3081308C - Lipase variants for pharmaceutical use - Google Patents
Lipase variants for pharmaceutical use Download PDFInfo
- Publication number
- CA3081308C CA3081308C CA3081308A CA3081308A CA3081308C CA 3081308 C CA3081308 C CA 3081308C CA 3081308 A CA3081308 A CA 3081308A CA 3081308 A CA3081308 A CA 3081308A CA 3081308 C CA3081308 C CA 3081308C
- Authority
- CA
- Canada
- Prior art keywords
- lipase
- seq
- enzyme
- amino acids
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090001060 Lipase Proteins 0.000 title claims abstract description 357
- 102000004882 Lipase Human genes 0.000 title claims abstract description 353
- 239000004367 Lipase Substances 0.000 title claims abstract description 350
- 235000019421 lipase Nutrition 0.000 title claims abstract description 350
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 90
- 150000001413 amino acids Chemical class 0.000 claims abstract description 87
- 102220479102 CD59 glycoprotein_N33Q_mutation Human genes 0.000 claims description 1127
- 102220097791 rs201753350 Human genes 0.000 claims description 414
- 102220598657 5-hydroxytryptamine receptor 1E_D27R_mutation Human genes 0.000 claims description 269
- 238000006467 substitution reaction Methods 0.000 claims description 98
- 102200108133 rs201753350 Human genes 0.000 claims description 63
- 102220056648 rs730881059 Human genes 0.000 claims description 41
- 102220257095 rs587779102 Human genes 0.000 claims description 36
- 102220105300 rs879254420 Human genes 0.000 claims description 29
- 102220536108 Serine/threonine-protein kinase OSR1_K46M_mutation Human genes 0.000 claims description 22
- 102220276634 rs1553131563 Human genes 0.000 claims description 20
- 235000019626 lipase activity Nutrition 0.000 claims description 16
- 102220020884 rs80356880 Human genes 0.000 claims description 15
- 102220330013 rs78488639 Human genes 0.000 claims description 10
- 102220184188 rs758665573 Human genes 0.000 claims description 9
- 102220104592 rs879254078 Human genes 0.000 claims description 9
- 102200080817 rs104894869 Human genes 0.000 claims description 7
- 102220028139 rs80357084 Human genes 0.000 claims description 7
- 102200131348 rs57983345 Human genes 0.000 claims description 5
- 102220363768 c.76A>C Human genes 0.000 claims description 4
- 239000004117 Lignosulphonate Substances 0.000 claims description 2
- 102220565484 Killer cell immunoglobulin-like receptor 2DL2_D96E_mutation Human genes 0.000 claims 22
- 102220084740 rs767734253 Human genes 0.000 claims 19
- 102220224785 rs755781709 Human genes 0.000 claims 8
- 102220358508 c.297A>T Human genes 0.000 claims 6
- 102220584273 Cellular tumor antigen p53_E56K_mutation Human genes 0.000 claims 2
- 102220370333 c.286G>A Human genes 0.000 claims 2
- 102220036799 rs587780049 Human genes 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 54
- 108091005804 Peptidases Proteins 0.000 abstract description 37
- 239000004365 Protease Substances 0.000 abstract description 37
- 239000003833 bile salt Substances 0.000 abstract description 36
- 238000000034 method Methods 0.000 abstract description 33
- 102000057297 Pepsin A Human genes 0.000 abstract description 32
- 108090000284 Pepsin A Proteins 0.000 abstract description 32
- 229940111202 pepsin Drugs 0.000 abstract description 32
- 108010065511 Amylases Proteins 0.000 abstract description 31
- 102000013142 Amylases Human genes 0.000 abstract description 31
- 230000029087 digestion Effects 0.000 abstract description 31
- 235000019418 amylase Nutrition 0.000 abstract description 30
- 239000004382 Amylase Substances 0.000 abstract description 27
- 229940093761 bile salts Drugs 0.000 abstract description 24
- 238000000338 in vitro Methods 0.000 abstract description 24
- 241000223258 Thermomyces lanuginosus Species 0.000 abstract description 11
- 208000035467 Pancreatic insufficiency Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 201000003883 Cystic fibrosis Diseases 0.000 abstract description 5
- 238000006731 degradation reaction Methods 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 206010033645 Pancreatitis Diseases 0.000 abstract description 4
- 230000001079 digestive effect Effects 0.000 abstract description 4
- 208000035475 disorder Diseases 0.000 abstract description 4
- 230000007935 neutral effect Effects 0.000 abstract description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 229940040461 lipase Drugs 0.000 description 265
- 102220104423 rs63749907 Human genes 0.000 description 88
- 102000004190 Enzymes Human genes 0.000 description 86
- 108090000790 Enzymes Proteins 0.000 description 86
- 235000001014 amino acid Nutrition 0.000 description 84
- 229940024606 amino acid Drugs 0.000 description 82
- 229940088598 enzyme Drugs 0.000 description 79
- 102220052839 rs73113102 Human genes 0.000 description 65
- 102220606460 C-reactive protein_G163V_mutation Human genes 0.000 description 59
- 102000035195 Peptidases Human genes 0.000 description 36
- 102220254290 rs1553156175 Human genes 0.000 description 31
- 230000006872 improvement Effects 0.000 description 27
- 235000019419 proteases Nutrition 0.000 description 26
- 235000005911 diet Nutrition 0.000 description 24
- 230000037213 diet Effects 0.000 description 24
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- 102220021416 rs80357110 Human genes 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 102220057725 rs374836770 Human genes 0.000 description 17
- 229920004890 Triton X-100 Polymers 0.000 description 16
- 229910052700 potassium Inorganic materials 0.000 description 16
- 102220105121 rs150066950 Human genes 0.000 description 16
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 102200121669 rs104894915 Human genes 0.000 description 15
- 102220475917 Oligophrenin-1_G91V_mutation Human genes 0.000 description 14
- 102220487741 Protein eyes shut homolog_D27N_mutation Human genes 0.000 description 14
- 102220412429 c.297A>C Human genes 0.000 description 14
- 239000000758 substrate Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 102220083998 rs551990619 Human genes 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 235000021588 free fatty acids Nutrition 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- 108010019160 Pancreatin Proteins 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940055695 pancreatin Drugs 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102220245301 rs1555596673 Human genes 0.000 description 9
- 102200110982 rs28931568 Human genes 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 7
- -1 Japan Substances 0.000 description 7
- 108010064785 Phospholipases Proteins 0.000 description 7
- 102000015439 Phospholipases Human genes 0.000 description 7
- 102220360655 c.170A>G Human genes 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 102220198277 rs1057519874 Human genes 0.000 description 7
- 102220041676 rs587779102 Human genes 0.000 description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- 102220564804 Killer cell immunoglobulin-like receptor 2DL2_N73D_mutation Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102100023105 Sialin Human genes 0.000 description 6
- 102220593678 Stromal interaction molecule 1_E87Q_mutation Human genes 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 235000011148 calcium chloride Nutrition 0.000 description 6
- 230000002538 fungal effect Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102220204637 rs137852883 Human genes 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- 241000228212 Aspergillus Species 0.000 description 5
- 102220524143 Cadherin-24_N26I_mutation Human genes 0.000 description 5
- 102220552927 Fidgetin-like protein 1_G163H_mutation Human genes 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 102200158812 rs104894225 Human genes 0.000 description 5
- 102200006121 rs1060501260 Human genes 0.000 description 5
- 102220082775 rs144148008 Human genes 0.000 description 5
- 102200027496 rs63751429 Human genes 0.000 description 5
- 102200101939 rs72554338 Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 241000981399 Aspergillus melleus Species 0.000 description 3
- 240000006439 Aspergillus oryzae Species 0.000 description 3
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000223198 Humicola Species 0.000 description 3
- 102220515651 Insulin-like growth factor I_R84E_mutation Human genes 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 102100037611 Lysophospholipase Human genes 0.000 description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102220517768 Methyl-CpG-binding domain protein 3-like 2B_D27Y_mutation Human genes 0.000 description 3
- 102220593541 PMS1 protein homolog 1_N11D_mutation Human genes 0.000 description 3
- 102220536901 PRKC apoptosis WT1 regulator protein_L69I_mutation Human genes 0.000 description 3
- 102220474144 Phosphatidylcholine-sterol acyltransferase_T37M_mutation Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 102220616017 Sterile alpha motif domain-containing protein 5_D96Y_mutation Human genes 0.000 description 3
- 102220600976 Syndecan-4_N26A_mutation Human genes 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 102220496421 Zinc finger CCHC domain-containing protein 24_E43V_mutation Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229940025131 amylases Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 3
- 229940062190 pancreas extract Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102220277043 rs1553408229 Human genes 0.000 description 3
- 102220271537 rs200383861 Human genes 0.000 description 3
- 102220041065 rs200979664 Human genes 0.000 description 3
- 102200028671 rs3765620 Human genes 0.000 description 3
- 102220045389 rs587782063 Human genes 0.000 description 3
- 102200116704 rs77587352 Human genes 0.000 description 3
- 102220087418 rs864622444 Human genes 0.000 description 3
- 102200158370 rs868333 Human genes 0.000 description 3
- 102220125026 rs886043836 Human genes 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- GGIDEJQGAZSTES-UHFFFAOYSA-N (4-nitrophenyl) octanoate Chemical compound CCCCCCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 GGIDEJQGAZSTES-UHFFFAOYSA-N 0.000 description 2
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102100035687 Bile salt-activated lipase Human genes 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 102220644676 Galectin-related protein_D96L_mutation Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 102220508063 Mitochondrial folate transporter/carrier_G91R_mutation Human genes 0.000 description 2
- 241000203622 Nocardiopsis Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102100027441 Nucleobindin-2 Human genes 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 102100035200 Phospholipase A and acyltransferase 4 Human genes 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 102220500768 Protein N-lysine methyltransferase METTL21D_D96V_mutation Human genes 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000228341 Talaromyces Species 0.000 description 2
- 241000223257 Thermomyces Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 108010087173 bile salt-stimulated lipase Proteins 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 102200161847 rs104894126 Human genes 0.000 description 2
- 102220312400 rs1555802310 Human genes 0.000 description 2
- 102200097285 rs199473487 Human genes 0.000 description 2
- 102200027488 rs63749907 Human genes 0.000 description 2
- 102200058234 rs80338731 Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 108010079522 solysime Proteins 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- HBOQXIRUPVQLKX-BBWANDEASA-N 1,2,3-trilinoleoylglycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)COC(=O)CCCCCCC\C=C/C\C=C/CCCCC HBOQXIRUPVQLKX-BBWANDEASA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 102220473558 ADP-ribosylation factor-like protein 2-binding protein_E56A_mutation Human genes 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 101001065065 Aspergillus awamori Feruloyl esterase A Proteins 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 102220560906 Ataxin-2_N73Y_mutation Human genes 0.000 description 1
- 241000223651 Aureobasidium Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102220568523 Clustered mitochondria protein homolog_E99S_mutation Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000221207 Filobasidium Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 241000171741 Humicola fuscoatra Species 0.000 description 1
- 241000223199 Humicola grisea Species 0.000 description 1
- 241001480714 Humicola insolens Species 0.000 description 1
- 241001350650 Humicola lutea Species 0.000 description 1
- 241000259838 Humicola nigrescens Species 0.000 description 1
- 241001373560 Humicola sp. Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102220642119 Lipoma-preferred partner_D96R_mutation Human genes 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 241001344133 Magnaporthe Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000226677 Myceliophthora Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102220526321 NHP2-like protein 1_G38K_mutation Human genes 0.000 description 1
- 241000233892 Neocallimastix Species 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241001221335 Nocardiopsis sp. Species 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 241001236817 Paecilomyces <Clavicipitaceae> Species 0.000 description 1
- 102100026367 Pancreatic alpha-amylase Human genes 0.000 description 1
- 102100033357 Pancreatic lipase-related protein 2 Human genes 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000235379 Piromyces Species 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 241000030452 Rasamsonia byssochlamydoides Species 0.000 description 1
- 241000959173 Rasamsonia emersonii Species 0.000 description 1
- 241000303962 Rhizopus delemar Species 0.000 description 1
- 241000588264 Rhizopus javanicus Species 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000222480 Schizophyllum Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000228178 Thermoascus Species 0.000 description 1
- 241001136490 Thermomyces dupontii Species 0.000 description 1
- 241001261109 Thermomyces ibadanensis Species 0.000 description 1
- 241000650705 Thermomyces verrucosus Species 0.000 description 1
- 241001494489 Thielavia Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108010058834 acylcarnitine hydrolase Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XCSQXCKDEVRTHN-UHFFFAOYSA-N cyclohexa-1,4-diene-1-carboxylic acid Chemical compound OC(=O)C1=CCC=CC1 XCSQXCKDEVRTHN-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000020979 dietary recommendations Nutrition 0.000 description 1
- 235000020930 dietary requirements Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 108091007735 digestive proteases Proteins 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000002641 enzyme replacement therapy Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 229920013746 hydrophilic polyethylene oxide Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- HBOQXIRUPVQLKX-UHFFFAOYSA-N linoleic acid triglyceride Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC HBOQXIRUPVQLKX-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 108010020132 microbial serine proteinases Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 108090000021 oryzin Proteins 0.000 description 1
- LVZSQWIWCANHPF-UHFFFAOYSA-N p-nitrophenyl palmitate Chemical group CCCCCCCCCCCCCCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LVZSQWIWCANHPF-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102200102592 rs104893740 Human genes 0.000 description 1
- 102200006128 rs559848002 Human genes 0.000 description 1
- 102220229111 rs759454598 Human genes 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 229940081852 trilinolein Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Detergent Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87119606P | 2006-12-21 | 2006-12-21 | |
| US60/871,196 | 2006-12-21 | ||
| CA2961041A CA2961041C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2961041A Division CA2961041C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3081308A1 CA3081308A1 (en) | 2008-07-03 |
| CA3081308C true CA3081308C (en) | 2024-02-20 |
Family
ID=38043020
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3081308A Active CA3081308C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
| CA2670643A Active CA2670643C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
| CA2961041A Active CA2961041C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2670643A Active CA2670643C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
| CA2961041A Active CA2961041C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8273348B2 (enExample) |
| EP (6) | EP2455460A3 (enExample) |
| JP (1) | JP5406040B2 (enExample) |
| KR (1) | KR20090101930A (enExample) |
| CN (2) | CN101743308B (enExample) |
| AR (1) | AR064494A1 (enExample) |
| AU (1) | AU2007337150A1 (enExample) |
| BR (1) | BRPI0721103A2 (enExample) |
| CA (3) | CA3081308C (enExample) |
| IL (1) | IL198893A0 (enExample) |
| MX (1) | MX2009006597A (enExample) |
| NO (1) | NO20092729L (enExample) |
| RU (1) | RU2009128067A (enExample) |
| TW (1) | TW200829698A (enExample) |
| WO (1) | WO2008079685A2 (enExample) |
| ZA (1) | ZA200903598B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005009677D1 (de) | 2004-03-22 | 2008-10-23 | Solvay Pharm Gmbh | Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden |
| MX2008000850A (es) | 2005-07-29 | 2008-03-18 | Solvay Pharm Gmbh | Procedimientos para la fabricacion de polvo de pancreatina esterilizada. |
| US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
| US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
| US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
| EP2455460A3 (en) | 2006-12-21 | 2012-12-26 | Novozymes A/S | Lipase variants for pharmaceutical use |
| CA2716692A1 (en) | 2008-02-29 | 2009-09-03 | Dsm Ip Assets B.V. | Lipases with high specificity towards short chain fatty acids and uses thereof |
| BRPI0909707A2 (pt) * | 2008-02-29 | 2015-08-25 | Procter & Gamble | Composição detergente que compreende lipase. |
| CN101990573B (zh) * | 2008-02-29 | 2014-01-22 | 诺维信公司 | 具有改进的稳定性的脂肪分解酶变体及编码该变体的多核苷酸 |
| WO2011072117A1 (en) | 2009-12-09 | 2011-06-16 | The Procter & Gamble Company | Fabric and home care products |
| US20140147895A1 (en) | 2011-07-22 | 2014-05-29 | Novozymes A/S | Processes for Pretreating Cellulosic Material and Improving Hydrolysis Thereof |
| US8268305B1 (en) | 2011-09-23 | 2012-09-18 | Bio-Cat, Inc. | Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase |
| ES2887576T3 (es) * | 2011-12-29 | 2021-12-23 | Novozymes As | Composiciones detergentes con variantes de lipasa |
| WO2013113622A1 (en) * | 2012-02-03 | 2013-08-08 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| CN104204198B (zh) * | 2012-04-02 | 2018-09-25 | 诺维信公司 | 脂肪酶变体以及编码其的多核苷酸 |
| CA2887898A1 (en) * | 2012-10-12 | 2014-04-17 | Danisco Us Inc. | Compositions and methods comprising a lipolytic enzyme variant |
| MX392247B (es) * | 2013-05-14 | 2025-03-24 | Novozymes As | Composiciones detergentes. |
| MX384253B (es) * | 2013-07-19 | 2025-03-14 | Danisco Us Inc | Composiciones y metodos que comprenden una variante de enzima lipolitica |
| US10287562B2 (en) * | 2014-11-20 | 2019-05-14 | Novoszymes A/S | Alicyclobacillus variants and polynucleotides encoding same |
| EP3227442B1 (en) * | 2014-12-05 | 2022-02-16 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| MX382218B (es) * | 2014-12-09 | 2025-03-13 | Novozymes As | Variantes de lipasa y polinucleotidos que las codifican. |
| EP3280818A2 (en) | 2015-04-07 | 2018-02-14 | Novozymes A/S | Methods for selecting enzymes having lipase activity |
| CA3175255A1 (en) * | 2015-07-01 | 2017-01-05 | Novozymes A/S | Methods of reducing odor |
| EP3317389B1 (en) * | 2015-07-03 | 2019-04-10 | Novozymes A/S | Detergent compositions with improved stability in the presence of sulfites |
| WO2018015295A1 (en) | 2016-07-18 | 2018-01-25 | Novozymes A/S | Lipase variants, polynucleotides encoding same and the use thereof |
| EP3575398A4 (en) * | 2017-01-30 | 2020-11-11 | Nippon Medical School Foundation | ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT |
| BR112020006224A2 (pt) | 2017-09-27 | 2020-10-13 | Novozymes A/S | variantes de lipase e composições de microcápsulas compreendendo tais variantes de lipase |
| CN111108195A (zh) * | 2017-09-27 | 2020-05-05 | 宝洁公司 | 包含脂肪酶的洗涤剂组合物 |
| US20210071157A1 (en) * | 2018-02-08 | 2021-03-11 | Novozymes A/S | Lipase Variants and Compositions Thereof |
| EP3837276A4 (en) * | 2018-08-16 | 2022-05-18 | Isolere Bio, Inc. | Genetically encoded polypeptide for affinity capture and purification of biologics |
| CN111334369B (zh) * | 2020-03-11 | 2022-10-21 | 陕西科技大学 | 一种酶法制备卵磷脂型pufa的方法 |
| WO2021260148A1 (en) * | 2020-06-24 | 2021-12-30 | Cilian Ag | New lipase enzyme |
| US20240035005A1 (en) * | 2020-10-29 | 2024-02-01 | Novozymes A/S | Lipase variants and compositions comprising such lipase variants |
| CN113846074B (zh) * | 2021-10-20 | 2022-10-21 | 南京林业大学 | 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用 |
| AU2023272468A1 (en) | 2022-05-14 | 2024-11-14 | Novonesis Plant Biosolutions A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
| CN119522274A (zh) * | 2022-06-24 | 2025-02-25 | 诺维信公司 | 脂肪酶变体和包含这样的脂肪酶变体的组合物 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK173590D0 (da) * | 1990-06-06 | 1990-07-19 | Novo Nordisk As | Rekombinante terapeutiske lipaser |
| US5869438A (en) | 1990-09-13 | 1999-02-09 | Novo Nordisk A/S | Lipase variants |
| BR9106839A (pt) | 1990-09-13 | 1993-07-20 | Novo Nordisk As | Variante de lipase,construcao de dna,vetor de expressao de recombinante,celula,planta,processo para produzir uma variante de lipase,aditivo e composicao de detergente |
| DK46693D0 (enExample) | 1993-04-23 | 1993-04-23 | Novo Nordisk As | |
| WO1992010755A1 (en) | 1990-12-05 | 1992-06-25 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
| EP0585285B1 (en) | 1991-05-01 | 1998-08-12 | Novo Nordisk A/S | Stabilized enzymes |
| DK39693D0 (da) | 1993-04-02 | 1993-04-02 | Novo Nordisk As | Enzym |
| EP0722491A1 (en) | 1993-10-04 | 1996-07-24 | Novo Nordisk A/S | An enzyme preparation comprising a modified enzyme |
| WO1995022615A1 (en) | 1994-02-22 | 1995-08-24 | Novo Nordisk A/S | A method of preparing a variant of a lipolytic enzyme |
| JPH10509324A (ja) | 1994-11-24 | 1998-09-14 | ノボ ノルディスク アクティーゼルスカブ | 抑制されたアレルゲン性を有するポリペプチドの製造のための方法 |
| AU697440B2 (en) | 1994-12-07 | 1998-10-08 | Novozymes A/S | Polypeptide with reduced allergenicity |
| AU710547B2 (en) | 1995-01-26 | 1999-09-23 | Novozymes A/S | Animal feed additives comprising xylanase |
| DE69633825T2 (de) | 1995-07-14 | 2005-11-10 | Novozymes A/S | Modifiziertes enzym mit lipolytischer aktivität |
| US6495357B1 (en) * | 1995-07-14 | 2002-12-17 | Novozyme A/S | Lipolytic enzymes |
| EP0851913B1 (en) | 1995-08-11 | 2004-05-19 | Novozymes A/S | Novel lipolytic enzymes |
| JP2002510963A (ja) | 1997-01-10 | 2002-04-09 | ノボザイムス アクティーゼルスカブ | スキンケア用酵素修飾体 |
| EP1017794A1 (en) | 1997-02-06 | 2000-07-12 | Novo Nordisk A/S | Polypeptide-polymer conjugates having added and/or removed attachment groups |
| ES2296336T3 (es) | 1997-06-25 | 2008-04-16 | Novozymes A/S | Polipeptido modificado. |
| ATE328070T1 (de) * | 1998-02-17 | 2006-06-15 | Novozymes As | Lipasevariante |
| AU3247699A (en) | 1998-02-17 | 1999-09-06 | Novo Nordisk A/S | Lipase variant |
| WO2000022103A1 (en) | 1998-10-13 | 2000-04-20 | Novozymes A/S | A modified polypeptide with reduced immune response |
| ATE390441T1 (de) | 1998-10-30 | 2008-04-15 | Novozymes As | Niedrigallergene proteinvarianten |
| ATE365210T1 (de) | 1998-10-30 | 2007-07-15 | Novozymes As | Glykosylierte proteine mit reduzierter allergenität |
| DK1131416T3 (da) | 1998-11-27 | 2009-10-26 | Novozymes As | Lipolytiske enzymvarianter |
| US7312062B2 (en) | 1998-11-27 | 2007-12-25 | Novozymes A/S | Lipolytic enzyme variants |
| DK1162995T3 (da) | 1999-03-17 | 2003-06-23 | Solvay Pharm Gmbh | Enzymer til behandling af diabetes mellitus type I |
| AU3420100A (en) * | 1999-03-31 | 2000-10-23 | Novozymes A/S | Lipase variant |
| CN100455663C (zh) * | 1999-03-31 | 2009-01-28 | 诺维信公司 | 脂肪酶变体 |
| AU777210C (en) | 2000-02-08 | 2005-08-04 | Dsm Ip Assets B.V. | Use of acid-stable subtilisin proteases in animal feed |
| AU2001254620A1 (en) | 2000-04-28 | 2001-11-12 | Novozymes A/S | Lipolytic enzyme variant |
| ES2323947T3 (es) | 2001-01-10 | 2009-07-28 | Novozymes A/S | Variante de enzima lipolitica. |
| AR032392A1 (es) | 2001-01-19 | 2003-11-05 | Solvay Pharm Gmbh | Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado. |
| CN1491278A (zh) | 2001-02-07 | 2004-04-21 | ŵά�Ź�˾ | 脂酶变体 |
| WO2003060112A1 (en) | 2002-01-16 | 2003-07-24 | Novozymes A/S | Lipolytic enzyme variants and method for their production |
| CA2514834A1 (en) | 2003-02-06 | 2004-08-19 | Novozymes A/S | Human heavy chain antibody expression in filamentous fungi |
| WO2004099400A2 (en) * | 2003-05-09 | 2004-11-18 | Novozymes A/S | Variant lipolytic ensymes |
| US20060251763A1 (en) | 2003-06-19 | 2006-11-09 | Patkar Shamkant A | Phospholipase variants |
| WO2004111224A1 (en) | 2003-06-19 | 2004-12-23 | Novozymes A/S | Improved proteases and methods for producing them |
| AR047440A1 (es) | 2004-01-21 | 2006-01-18 | Novozymes As | Produccion de un anticuerpo monoclonal en un hongo heterocarion o una celula huesped fungal |
| DE602005009677D1 (de) | 2004-03-22 | 2008-10-23 | Solvay Pharm Gmbh | Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden |
| HUE031245T2 (en) | 2004-10-14 | 2017-06-28 | Lilly Co Eli | Preparations containing lipase, protease and amylase for the treatment of pancreatic insufficiency |
| WO2006084470A2 (en) | 2005-02-10 | 2006-08-17 | Novozymes A/S | Enzymatic enantioselective ester or amide hydrolysis or synthesis |
| CA2612648A1 (en) * | 2005-06-24 | 2006-12-28 | Novozymes A/S | Lipases for pharmaceutical use |
| EP1896058A2 (en) | 2005-06-24 | 2008-03-12 | Novozymes A/S | Proteases for pharmaceutical use |
| EP1896057A2 (en) | 2005-06-24 | 2008-03-12 | Novozymes A/S | Amylases for pharmaceutical use |
| WO2007080197A2 (en) * | 2006-01-16 | 2007-07-19 | Novozymes A/S | Immobilised enzymes |
| EP2371948B1 (en) * | 2006-01-23 | 2017-04-19 | Novozymes A/S | Lipase variants |
| CA2635927A1 (en) | 2006-01-23 | 2007-08-02 | The Procter And Gamble Company | A composition comprising a lipase and a bleach catalyst |
| EP2455460A3 (en) * | 2006-12-21 | 2012-12-26 | Novozymes A/S | Lipase variants for pharmaceutical use |
-
2007
- 2007-12-12 EP EP12155315A patent/EP2455460A3/en not_active Withdrawn
- 2007-12-12 CN CN200780051638.6A patent/CN101743308B/zh active Active
- 2007-12-12 CA CA3081308A patent/CA3081308C/en active Active
- 2007-12-12 US US12/519,868 patent/US8273348B2/en active Active
- 2007-12-12 AU AU2007337150A patent/AU2007337150A1/en not_active Abandoned
- 2007-12-12 CN CN201510504893.8A patent/CN105112386A/zh active Pending
- 2007-12-12 EP EP07869130A patent/EP2099907A2/en not_active Withdrawn
- 2007-12-12 CA CA2670643A patent/CA2670643C/en active Active
- 2007-12-12 WO PCT/US2007/087168 patent/WO2008079685A2/en not_active Ceased
- 2007-12-12 EP EP10172609.9A patent/EP2261328B1/en active Active
- 2007-12-12 KR KR1020097014850A patent/KR20090101930A/ko not_active Withdrawn
- 2007-12-12 EP EP12155319.2A patent/EP2455462B1/en active Active
- 2007-12-12 EP EP12155317.6A patent/EP2455461B1/en active Active
- 2007-12-12 EP EP12155294.7A patent/EP2455459B1/en active Active
- 2007-12-12 MX MX2009006597A patent/MX2009006597A/es not_active Application Discontinuation
- 2007-12-12 BR BRPI0721103-1A patent/BRPI0721103A2/pt not_active IP Right Cessation
- 2007-12-12 RU RU2009128067/10A patent/RU2009128067A/ru not_active Application Discontinuation
- 2007-12-12 CA CA2961041A patent/CA2961041C/en active Active
- 2007-12-12 JP JP2009543078A patent/JP5406040B2/ja active Active
- 2007-12-18 TW TW096148377A patent/TW200829698A/zh unknown
- 2007-12-21 AR ARP070105859A patent/AR064494A1/es not_active Application Discontinuation
-
2009
- 2009-05-21 IL IL198893A patent/IL198893A0/en unknown
- 2009-05-25 ZA ZA200903598A patent/ZA200903598B/xx unknown
- 2009-07-20 NO NO20092729A patent/NO20092729L/no not_active Application Discontinuation
-
2012
- 2012-08-16 US US13/587,043 patent/US9029115B2/en active Active
-
2015
- 2015-04-06 US US14/679,563 patent/US9539311B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3081308C (en) | Lipase variants for pharmaceutical use | |
| US20090047266A1 (en) | Lipases for Pharmaceutical Use | |
| US8455235B2 (en) | Protease variants for pharmaceutical use | |
| AU2013203500B2 (en) | Lipase variants for pharmaceutical use | |
| AU2013200626B2 (en) | Lipase variants for pharmaceutical use | |
| HK1141553A (en) | Lipase variants for pharmaceutical use | |
| HK1145697A (en) | Protease variants for pharmaceutical use | |
| HK1113174A (en) | Lipases for pharmaceutical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200520 |
|
| EEER | Examination request |
Effective date: 20200520 |
|
| EEER | Examination request |
Effective date: 20200520 |
|
| EEER | Examination request |
Effective date: 20200520 |
|
| EEER | Examination request |
Effective date: 20200520 |
|
| EEER | Examination request |
Effective date: 20200520 |
|
| EEER | Examination request |
Effective date: 20200520 |
|
| EEER | Examination request |
Effective date: 20200520 |
|
| EEER | Examination request |
Effective date: 20200520 |
|
| EEER | Examination request |
Effective date: 20200520 |
|
| EEER | Examination request |
Effective date: 20200520 |